{"entity":{"id":"nct04150497","kind":"trial","name":"Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)","aka":[],"tldr":"A phase 1/2 trial of UCART22 in acute lymphoblastic leukaemia, run by Cellectis S.A., now recruiting.","summary":"Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01) is a phase 1/2 interventional study registered as NCT04150497 by Cellectis S.A., with 52 participants planned, started 2019-10-14 and due to reach its primary completion in 2026-06-30. Interventions recorded: UCART22 and CLLS52.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04150497","url":"https://clinicaltrials.gov/study/NCT04150497"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["all-leukemia"],"sections":[],"technologies":[],"targets":[],"drugs":["ucart22"],"companies":["cellectis-s-a"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04150497","phase":"1/2","setting":"Open Label Dose-escalation and Dose-expansion Study to Evaluate the Safety, Expansion, Persistence and Clinical Activity of UCART22 (Allogeneic Engineered T-cells Expressing Anti-CD22 Chimeric Antigen Receptor) in Patients With Relapsed or refractoryCD22+ B-cell Acute Lymphoblastic Leukemia (B-ALL)","sponsor":"Cellectis S.A.","enrolled":52,"outcomes":[]},"route":"/trials/nct04150497/","neighbours":{"cancer":[{"id":"all-leukemia","kind":"cancer","name":"Acute lymphoblastic leukaemia","route":"/cancers/all-leukemia/"}],"drug":[{"id":"ucart22","kind":"drug","name":"UCART22","route":"/drugs/ucart22/"}],"company":[{"id":"cellectis-s-a","kind":"company","name":"Cellectis S.A.","route":"/companies/cellectis-s-a/"}]}}